Why “Anti-Aging” Supplement Claims Deserve Extra Scrutiny

“Anti-aging” is one of the most-used phrases in the supplement industry and also one of the most legally loaded, because aging itself sits in an unusual spot in FDA and FTC rules: it’s not a disease, but claims about reversing, slowing, or repairing its effects can slide into disease-claim territory faster than most marketers realize — and faster than most readers realize either. This article isn’t a product review. It’s a plain-language walkthrough of the actual federal rule that draws this line, plus two concrete enforcement cases showing what happens when a company crosses it, so that both this site’s own future reviews and its readers evaluating other brands have a real framework rather than a vague sense that “some claims are too good to be true.”

The short version

• Aging itself is not classified as a disease under FDA’s own regulation — but claims about affecting the abnormal effects of aging, or specific age-related conditions, can legally count as disease claims, which pushes a product out of “dietary supplement” territory and into “unapproved drug” territory.
• The actual rule is 21 CFR 101.93, which distinguishes permitted “structure/function” claims (describing how an ingredient supports the body’s normal structure or function) from prohibited “disease claims” (describing an effect on a disease, its symptoms, or “an abnormal condition associated with a natural process” when that condition is uncommon or can cause significant or permanent harm) — language that maps directly onto how “anti-aging” products are often marketed.
• A real, concrete example: in 2020, the FTC settled charges against the sellers of a supplement called ReJuvenation, whose marketing claimed the product could “reverse the aging process,” repair damage from heart attacks, Alzheimer’s, Parkinson’s, and Crohn’s disease, and increase human growth hormone and stem cell counts in the body. The settlement required $660,000 in consumer refunds and separate judgments of $993,416 and $2.4 million against the individual defendants (both substantially suspended contingent on smaller payments), plus a permanent prohibition on making such claims without scientific substantiation.
• The specific language matters more than the general topic. A claim like “supports skin’s natural collagen production” is a permitted structure/function claim. A claim like “reverses the visible signs of aging” or “repairs cellular damage” risks crossing into disease-claim or drug-claim territory, particularly when paired with references to named conditions, before/after photography implying treatment, or citations to disease-focused research.
• This is why this site’s own editorial approach treats “anti-aging” framing as a flag requiring extra care, not a reason to avoid the category — plenty of well-evidenced, honestly marketed structure/function claims exist in this space (see our companion articles on collagen and NAD+ precursors); the issue is specifically the gap between what’s legally and scientifically defensible and what more aggressive marketing implies.

The actual rule: structure/function claims vs. disease claims

Dietary supplements are legally permitted to make “structure/function” claims — statements describing how a nutrient or ingredient supports the body’s normal structure or function (e.g., “supports healthy joints,” “helps maintain skin elasticity”). What they cannot legally do, without being regulated as an unapproved new drug, is make “disease claims” — statements that a product diagnoses, treats, cures, prevents, or mitigates a disease.

The regulation governing this distinction, 21 CFR 101.93, defines a “disease” as damage to an organ, part, structure, or system of the body such that it doesn’t function properly, or a state of health leading to that dysfunction — explicitly excluding classical nutrient-deficiency diseases (like scurvy) from this definition. It then lists specific criteria FDA uses to determine whether a statement counts as an implicit or explicit disease claim, including whether the product claims an effect on a specific disease, on the “characteristic signs or symptoms” of a disease, or — and this is the criterion most directly relevant to “anti-aging” marketing specifically — whether it claims an effect on “an abnormal condition associated with a natural state or process, if the abnormal condition is uncommon or can cause significant or permanent harm.”

That last criterion is worth sitting with, because it’s precisely the tension “anti-aging” claims live in. Aging is a normal, universal biological process — not itself a disease. But specific abnormal consequences that can accompany aging (certain forms of cognitive decline, osteoporosis-related fractures, macular degeneration, and so on) can be diseases in their own right. A supplement marketed to address the normal, gradual signs of aging (fine lines, some loss of skin elasticity) is generally on structure/function ground. The same supplement marketed as reversing, repairing, or preventing more serious, named age-related conditions is generally not — regardless of how the marketing frames the underlying ingredient.

The regulation also specifies exactly what triggers this distinction beyond direct wording: the product’s name, references to ingredients well known for treating disease, citations of disease-focused research presented in a way that implies treatment, and even “pictures, vignettes, symbols, or other means” can each independently turn an otherwise-permitted claim into a disease claim, depending on context. This matters because a lot of “anti-aging” marketing operates through implication — a stock photo of a person going from frail to vigorous, a citation to a study about a specific disease’s biology used to imply the product treats that disease — rather than a single explicit sentence a compliance reviewer could flag in isolation.

What this looks like when it goes wrong: the ReJuvenation case

The clearest, most concrete illustration of this line being crossed is a 2020 FTC enforcement action against the marketers of a product called ReJuvenation — made of amino acids and herbal extracts, sold via direct mail and online advertising between 2014 and 2016 (and beyond, under new ownership starting in 2016).

According to the FTC’s complaint, ReJuvenation’s marketing claimed the product could reverse the aging process and repair age-related damage to the body by increasing human growth hormone and stem cell counts, and that it could repair or reverse damage from a specific, named list of serious diseases: heart attacks, heart disease, blindness, brain damage from stroke, Alzheimer’s disease, Parkinson’s disease, deafness, and Crohn’s disease, among others. The complaint also cited claims of reduced wrinkle appearance and improved memory and cognitive functioning.

This is a textbook illustration of exactly the pattern 21 CFR 101.93 is written to catch: a product marketed with plausible-sounding structure/function language (“age-related damage,” “cellular repair”) that, on closer inspection, explicitly names specific diseases it claims to treat or reverse — moving well past permitted territory. The FTC’s resulting settlement (announced February 5, 2020) required $660,000 be made available for consumer refunds, permanently prohibited the defendants from making such claims without scientific substantiation, and imposed separate monetary judgments against the individual defendants (a $993,416 judgment against one defendant, suspended to $60,000 upon payment; a $2.4 million judgment against another, suspended to $600,000). The FTC’s own public statement on the case was blunt: “If you make those kinds of claims, you’d better have credible science to back it up or the FTC is coming for you.”

This case is now several years old, but the pattern it illustrates — vague “anti-aging” or “cellular repair” language sitting on top of a list of specific disease claims — is a durable one across the category, not a one-time incident.

What to look for, as a practical checklist

Based directly on the regulatory criteria above, a few concrete patterns are worth watching for in any anti-aging product’s marketing, including this site’s own future content:

• Named diseases or specific medical conditions appearing anywhere in the marketing (Alzheimer’s, heart disease, osteoporosis, macular degeneration, etc.) alongside a supplement claim — a strong signal the claim has moved from structure/function into disease-claim territory.
• Language like “reverse,” “repair,” “cure,” or “eliminate” applied to aging itself or its effects, rather than language like “support,” “maintain,” or “help with the appearance of.”
• Claims about affecting cellular-level processes tied to specific disease mechanisms (rather than general, normal-aging structure/function support) — particularly when paired with citations to disease-focused research.
• Before/after imagery, testimonials, or specific numeric claims (“reduces wrinkles by X%,” “reverses skin age by Y years”) that imply a treatment effect beyond ordinary cosmetic support.
• “Clinically proven” or “scientifically proven” language attached to disease-reversal claims specifically, as opposed to more modest, substantiated structure/function claims — the ReJuvenation case’s settlement order specifically targeted this combination.

None of this means every “anti-aging” product is making illegal claims, and it doesn’t mean structure/function claims are weak or meaningless — the collagen and NAD+ articles on this site cover real, if sometimes limited, human evidence for specific, appropriately framed claims in this exact category. The point of this article is narrower and more durable: “anti-aging” is a category where the gap between a legally and scientifically defensible claim and an overreaching one is unusually easy to cross without realizing it, and readers evaluating any product in this space — on this site or elsewhere — benefit from knowing specifically what that line looks like.

What we could not check

• We did not conduct a comprehensive survey of all FTC or FDA enforcement actions against anti-aging supplement marketers — the ReJuvenation case is presented as one clear, well-documented, and directly on-point illustration, not as the only or most recent such case; more recent enforcement actions likely exist and were not systematically reviewed here.
• We did not review FDA’s separate warning-letter enforcement track (as distinct from FTC’s consumer-protection settlements) for anti-aging-specific supplement cases in this pass.
• This article does not constitute legal advice, and nothing here should be read as a complete compliance checklist for any specific product’s marketing — it’s intended to help readers (and this site’s own future content) recognize the general pattern, not substitute for actual legal review of specific claims.

Our rating, and why

Not applicable. This article evaluates a regulatory framework, not a supplement, ingredient, or health claim, so this site’s evidence-classification scale doesn’t apply to it in the way it does elsewhere. Its purpose is to give readers (and this site’s own reviewers) a concrete, citable standard for recognizing when “anti-aging” language has moved from a legitimate structure/function claim into disease-claim territory — grounded directly in the actual federal regulation and a real enforcement case, not a general impression of “some claims seem exaggerated.”

Sources

1. U.S. Food and Drug Administration. 21 CFR 101.93 — Certain types of statements for dietary supplements. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-101/subpart-F/section-101.93 (read in full)
2. Federal Trade Commission. FTC Takes Action to Stop Anti-Aging “Cure-All” Marketers From Making Baseless Health Claims. Press release, February 5, 2020. https://www.ftc.gov/news-events/news/press-releases/2020/02/ftc-takes-action-stop-anti-aging-cure-all-marketers-making-baseless-health-claims (read in full)